Concepedia

Author

Marco Cerrano

Azienda Ospedaliera Citta' della Salute e della Scienza di TorinoORCID

Also Known As

Cerrano M, Cerrano Marco, Isabella Capodanno, M Cerrano, M. Cerrano, Marco Cerrano, marco cerrano

136

Publications

1.5K

Citations

19

H-Index

43

Concepts

All Affiliations

Azienda Ospedaliera Citta' della Salute e della Scienza di TorinoFondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicoIstituti di Ricovero e Cura a Carattere ScientificoUniversity of TurinSapienza University of Rome
MC

About

Marco Cerrano is an author at Azienda Ospedaliera Citta' della Salute e della Scienza di Torino specializing in hematology, medicine, and health sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

410

2

Health Sciences

8

8

371

3

Blood Transplantation

2

2

86

4

Public Health

1

1

11

5

Cellular Therapies

1

1

67

Marco Cerrano

×

22

Publications

866

Citations

14

H-Index

YearCitations

Germline DDX41 mutations define a significant entity within adult MDS/AML patients

Marie Sébert, Marie Passet, Anna Raimbault,

Blood

2019

202

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP

Michele Baccarani, Elisabetta Abruzzese, Vincenzo Accurso,

Blood Advances

2019

89

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

Sabina Chiaretti, Monica Messina, Irene Della Starza,

Haematologica

2020

78

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

Carmen Fava, Giovanna Rege‐Cambrin, Irene Dogliotti,

Haematologica

2019

75

Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study

Anna Candoni, Davide Lazzarotto, Felicetto Ferrara,

American Journal of Hematology

2020

67

CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program

Fabio Guolo, Luana Fianchi, Paola Minetto,

Blood Cancer Journal

2020

56

Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study

Federica Martella, Marco Cerrano, Daniela Di Cuonzo,

Annals of Hematology

2022

36

Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).

Lionel Adès, Justin M. Watts, Atanas Radinoff,

Journal of Clinical Oncology

2020

33

The use of erythropoiesis‐stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib

Elena Crisà, Daniela Cilloni, Elena Maria Elli,

British Journal of Haematology

2018

30

Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis

Marco Cerrano, Sylvie Chevret, Emmanuel Raffoux,

Annals of Hematology

2023

28

Page 1